nach oben

Erschienen in:

28.12.2015 | Original Article

Is it possible to detect an improvement in cancer pain management? A comparison of two Norwegian cross-sectional studies conducted 5 years apart

verfasst von: Morten Thronæs, Sunil X. Raj, Cinzia Brunelli, Sigrun Saur Almberg, Ola Magne Vagnildhaug, Susanna Bruheim, Birgit Helgheim, Stein Kaasa, Anne Kari Knudsen

Erschienen in: Supportive Care in Cancer | Ausgabe 6/2016

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Cancer pain (CP) management is challenging. In recent years, efforts were undertaken to achieve better CP management, e.g. clinical research, new treatment modalities, development of guidelines, education and focus on implementation. The aim of the present study was to compare the prevalence and characteristics of pain and breakthrough pain (BTP) between cross-sectional studies conducted in 2008 and 2014. It was hypothesized that an improvement in pain control would be observed the years in between.

Methods

Two cross-sectional studies were conducted where adult cancer patients answered questions from Brief Pain Inventory and the Alberta Breakthrough Pain Assessment Tool for cancer patients. Physicians reported socio-demographic and medical data. Regression models were applied for analysis.

Results

In total, 168 inpatients, 92 in 2008 and 76 in 2014, and 675 outpatients, 301 in 2008 and 374 in 2014, were included. The patient characteristics of the samples were comparable. Prevalence of CP among inpatients was 55 % in 2008 and 53 % in 2014, and among outpatients, 39 and 35 %, respectively. Inpatients reported average pain intensity (0–10 numerical rating scale, NRS) of 3.60 (standard deviation, SD 1.84) (2008) and 4.08 (SD 2.11) (2014); prevalence of BTP was 52 % (2008) and 41 % (2014). For outpatients, average pain intensity was 3.60 (SD 2.04) (2008) and 3.86 (SD 2.20) (2014); prevalence of BTP was 43 % (2008) and 37 % (2014). None of the differences were statistically significant.

Conclusion

Unexpectedly, no improvement in pain control was observed. Efforts are still needed to improve cancer pain management.

Donaldson N, Joranson D, Sbanotto A, Teoh N, Twycross R, Ventafridda V. Cancer pain relief. Cancer pain relief. second edition ed. Genova: World Health Organisation (WHO); 1996. p. 1–36.

Stjernsward J (1988) WHO cancer pain relief programme. Cancer Surv 7(1):195–208PubMed

Zech DF, Grond S, Lynch J, Hertel D, Lehmann KA (1995) Validation of World Health Organization guidelines for cancer pain relief: a 10-year prospective study. Pain 63(1):65–76CrossRefPubMed

van den Beuken-van Everdingen MH, de Rijke JM, Kessels AG, Schouten HC, van Kleef M, Patijn J (2007) Prevalence of pain in patients with cancer: a systematic review of the past 40 years. Ann Oncol 18(9):1437–49CrossRef

Porter LS, Keefe FJ (2011) Psychosocial issues in cancer pain. Curr Pain Headache Rep 15(4):263–70CrossRefPubMed

Knudsen AK, Brunelli C, Klepstad P, Aass N, Apolone G, Corli O et al (2012) Which domains should be included in a cancer pain classification system? Analyses of longitudinal data. Pain 153(3):696–703CrossRefPubMed

Fainsinger RL, Nekolaichuk C, Lawlor P, Hagen N, Bercovitch M, Fisch M et al (2010) An international multicentre validation study of a pain classification system for cancer patients. Eur J Cancer 46(16):2896–904CrossRefPubMed

Cleeland CS, Ryan KM (1994) Pain assessment: global use of the Brief Pain Inventory. Ann Acad Med Singapore 23(2):129–38PubMed

Bennett M (2001) The LANSS Pain Scale: the Leeds assessment of neuropathic symptoms and signs. Pain 92(1–2):147–57CrossRefPubMed

10.

Gilbody S, Richards D, Brealey S, Hewitt C (2007) Screening for depression in medical settings with the Patient Health Questionnaire (PHQ): a diagnostic meta-analysis. J Gen Intern Med 22(11):1596–602CrossRefPubMedPubMedCentral

11.

Spitzer RL, Kroenke K, Williams JB (1999) Validation and utility of a self-report version of PRIME-MD: the PHQ primary care study. Primary Care Evaluation of Mental Disorders. Patient Health Questionnaire. JAMA 282(18):1737–44CrossRefPubMed

12.

Watanabe SM, Nekolaichuk C, Beaumont C, Johnson L, Myers J, Strasser F (2011) A multicenter study comparing two numerical versions of the Edmonton Symptom Assessment System in palliative care patients. J Pain Symptom Manage 41(2):456–68CrossRefPubMed

13.

Sigurdardottir KR, Kaasa S, Rosland JH, Bausewein C, Radbruch L, Haugen DF et al (2014) The European Association for Palliative Care basic dataset to describe a palliative care cancer population: results from an international Delphi process. Palliat Med 28(6):463–73CrossRefPubMed

14.

Deandrea S, Corli O, Consonni D, Villani W, Greco MT, Apolone G (2013) Prevalence of breakthrough cancer pain: a systematic review and a pooled analysis of published literature. J Pain Symptom Manage

15.

Caraceni A, Martini C, Zecca E, Portenoy RK, Ashby MA, Hawson G et al (2004) Breakthrough pain characteristics and syndromes in patients with cancer pain. An international survey. Palliat Med 18(3):177–83CrossRefPubMed

16.

Zeppetella G (2011) Breakthrough pain in cancer patients. Clin Oncol (R Coll Radiol) 23(6):393–8CrossRef

17.

Haugen DF, Hjermstad MJ, Hagen N, Caraceni A, Kaasa S (2010) Assessment and classification of cancer breakthrough pain: a systematic literature review. Pain 149(3):476–82CrossRefPubMed

18.

Kwon JH (2014) Overcoming barriers in cancer pain management. J Clin Oncol 32(16):1727–33CrossRefPubMed

19.

Caraceni A, Hanks G, Kaasa S, Bennett MI, Brunelli C, Cherny N et al (2012) Use of opioid analgesics in the treatment of cancer pain: evidence-based recommendations from the EAPC. Lancet Oncol 13(2):e58–e68CrossRefPubMed

20.

(2013) Directorate of Health: Nasjonalt handlingsprogram med retningslinjer for palliasjon i kreftomsorgen [Norwegian guidelines for palliative care]. IS-2101

21.

Zeppetella G, Davies AN (2013) Opioids for the management of breakthrough pain in cancer patients. Cochrane Database Syst Rev 10:CD004311PubMed

22.

Norwegian Ministry of Health and Care Services: the coordination reform. Report No. 47. 2008–2009.

23.

Raj SX, Thronaes M, Brunelli C, Hjermstad MJ, Klepstad P, Kaasa S (2014) A cross-sectional study on prevalence of pain and breakthrough pain among an unselected group of outpatients in a tertiary cancer clinic. Support Care Cancer 22(7):1965–71CrossRefPubMed

24.

Hagen NA, Stiles C, Nekolaichuk C, Biondo P, Carlson LE, Fisher K et al (2008) The Alberta Breakthrough Pain Assessment Tool for cancer patients: a validation study using a Delphi process and patient think-aloud interviews. J Pain Symptom Manage 35(2):136–52CrossRefPubMed

25.

Karnofsky DA, Burchenal J (1949) The clinical evaluation of chemotherapeutic agents in cancer. In: MacLeod C, editor. Evaluation of chemotherapeutic agents. Columbia Univ Press; p. 196.

26.

Buccheri G, Ferrigno D, Tamburini M (1996) Karnofsky and ECOG performance status scoring in lung cancer: a prospective, longitudinal study of 536 patients from a single institution. Eur J Cancer 32A(7):1135–41CrossRefPubMed

27.

Holtan A, Aass N, Nordoy T, Haugen DF, Kaasa S, Mohr W et al (2007) Prevalence of pain in hospitalised cancer patients in Norway: a national survey. Palliat Med 21(1):7–13CrossRefPubMed

28.

Te Boveldt N, Vernooij-Dassen M, Burger N, Ijsseldijk M, Vissers K, Engels Y (2013) Pain and its interference with daily activities in medical oncology outpatients. Pain Physician 16(4):379–89

29.

Davies A, Zeppetella G, Andersen S, Damkier A, Vejlgaard T, Nauck F et al (2011) Multi-centre European study of breakthrough cancer pain: pain characteristics and patient perceptions of current and potential management strategies. Eur J Pain 15(7):756–63CrossRefPubMed

30.

Bedard G, Hawley P, Zhang L, Slaven M, Gagnon P, Bisland S et al (2013) A survey of Canadian cancer patients’ perspectives on the characteristics and treatment of breakthrough pain. Support Care Cancer 21(9):2557–63CrossRefPubMed

31.

Bennett MI, Bagnall AM, Jose CS (2009) How effective are patient-based educational interventions in the management of cancer pain? Systematic review and meta-analysis. Pain 143(3):192–9CrossRefPubMed

32.

Lovell MR, Luckett T, Boyle FM, Phillips J, Agar M, Davidson PM (2014) Patient education, coaching, and self-management for cancer pain. J Clin Oncol 32(16):1712–20CrossRefPubMed

33.

Te Boveldt N, Vernooij-Dassen M, Besse K, Vissers K, Engels Y (2014) Adoptation of an evidence-based clinical practice guideline in cancer pain management by medical oncologists: a case vignette study. Support Care Cancer

34.

Lovell M, Agar M, Luckett T, Davidson PM, Green A, Clayton J (2013) Australian survey of current practice and guideline use in adult cancer pain assessment and management: perspectives of palliative care physicians. J Palliat Med 16(11):1403–9CrossRefPubMedPubMedCentral

35.

Sanders S, Mackin ML, Reyes J, Herr K, Titler M, Fine P et al (2010) Implementing evidence-based practices: considerations for the hospice setting. Am J Hosp Palliat Care 27(6):369–76CrossRefPubMedPubMedCentral

36.

Du Pen SL, Du Pen AR, Polissar N, Hansberry J, Kraybill BM, Stillman M et al (1999) Implementing guidelines for cancer pain management: results of a randomized controlled clinical trial. J Clin Oncol 17(1):361–70PubMed

37.

Du Pen AR, Du Pen S, Hansberry J, Miller-Kraybill B, Millen J, Everly R et al (2000) An educational implementation of a cancer pain algorithm for ambulatory care. Pain Manag Nurs 1(4):116–28CrossRefPubMed

38.

Vanhaecht K, De Witte K, Panella M, Sermeus W (2009) Do pathways lead to better organized care processes? J Eval Clin Pract 15(5):782–8CrossRefPubMed

39.

Vanhaecht K, Ovretveit J, Elliott MJ, Sermeus W, Ellershaw J, Panella M (2012) Have we drawn the wrong conclusions about the value of care pathways? Is a Cochrane review appropriate? Eval Health Prof 35(1):28–42CrossRefPubMed

40.

Rotter T, Kinsman L, James E, Machotta A, Willis J, Snow P et al (2012) The effects of clinical pathways on professional practice, patient outcomes, length of stay, and hospital costs: Cochrane systematic review and meta-analysis. Eval Health Prof 35(1):3–27CrossRefPubMed

41.

omsorgsdepartementet H-o. Sammen mot kreft, Nasjonal kreftstrategi 2013–2017 [21.05 2015]. Available from: https://www.regjeringen.no/contentassets/07cd14ff763444a3997de1570b85fad1/kreftstrategien_2013.pdf.

42.

Brusamento S, Legido-Quigley H, Panteli D, Turk E, Knai C, Saliba V et al (2012) Assessing the effectiveness of strategies to implement clinical guidelines for the management of chronic diseases at primary care level in EU Member States: a systematic review. Health Policy 107(2–3):168–83CrossRefPubMed

43.

Boaz A, Baeza J, Fraser A, European Implementation Score Collaborative G (2011) Effective implementation of research into practice: an overview of systematic reviews of the health literature. BMC Res Notes 4:212CrossRefPubMedPubMedCentral

44.

Fixsen D, Scott V, Blase K, Naoom S, Wagar L (2011) When evidence is not enough: the challenge of implementing fall prevention strategies. J Saf Res 42(6):419–22CrossRef

45.

Roshanov PS, Fernandes N, Wilczynski JM, Hemens BJ, You JJ, Handler SM et al (2013) Features of effective computerised clinical decision support systems: meta-regression of 162 randomised trials. BMJ 346:f657CrossRefPubMed

Titel: Is it possible to detect an improvement in cancer pain management? A comparison of two Norwegian cross-sectional studies conducted 5 years apart
verfasst von: Morten Thronæs
Sunil X. Raj
Cinzia Brunelli
Sigrun Saur Almberg
Ola Magne Vagnildhaug
Susanna Bruheim
Birgit Helgheim
Stein Kaasa
Anne Kari Knudsen
Publikationsdatum: 28.12.2015
Verlag: Springer Berlin Heidelberg
Erschienen in: Supportive Care in Cancer / Ausgabe 6/2016
Print ISSN: 0941-4355
Elektronische ISSN: 1433-7339
DOI: https://doi.org/10.1007/s00520-015-3064-3

Neu im Fachgebiet Onkologie

25.04.2024 | Nierenkarzinom | Nachrichten

Springer Medizin

Is it possible to detect an improvement in cancer pain management? A comparison of two Norwegian cross-sectional studies conducted 5 years apart

Abstract

Purpose

Methods

Results

Conclusion

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie

Springer Medizin

Abstract

Purpose

Methods

Results

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 6/2016

Acceptability and feasibility of an e-mental health intervention for parents of childhood cancer survivors: “Cascade”

Safe and effective deodorization of malodorous fungating tumors using topical metronidazole 0.75 % gel (GK567): a multicenter, open-label, phase III study (RDT.07.SRE.27013)

Primary care physicians and oncologists are partners in cancer announcement

Chemotherapy-induced neuropathy in multiple myeloma: influence on quality of life and development of a questionnaire to compose common toxicity criteria grading for use in daily clinical practice

Psychological flexibility correlates with patient-reported outcomes independent of clinical or sociodemographic characteristics

Clinical safety of tbo-filgrastim, a short-acting human granulocyte colony-stimulating factor

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie